PPARs and their effects on the cardiovascular system

Clinical and Experimental Hypertension

Volumn 33, Issue 5, 2011, Pages 287-293

  Oyekan, Adebayo ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Peroxisome proliferator activated receptor (PPAR); PPAR response element (PPRE); Retinoid receptor (RXR); Transactivation; Transrepression

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; ROSIGLITAZONE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; VASODILATATION;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; HYPERTENSION; INFLAMMATION; INFLAMMATION MEDIATORS; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; VENTRICULAR REMODELING;

EID: 79960970364     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.531845     Document Type: Article

References (70)

1. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514. (Pubitemid 28160438)
2. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82. (Pubitemid 28079218)
3. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999a; 85:394-402. (Pubitemid 29409616)
4. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C.The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator activated receptor α. Molecular Endocrinol 2004;18:1906-1918. (Pubitemid 39006498)
5. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Bioc Biophys Res Comm 1998;2:370-374. (Pubitemid 28412605)
6. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circ 1998a; 98:2088-2093. (Pubitemid 28512236)
7. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273:25573-25580. (Pubitemid 28475776)
8. Desvergne B, Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999;20(5): 649-688. (Pubitemid 30650602)
9. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424. (Pubitemid 30367411)
10. Chait A, Brazg RL, Tribble DL. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern. B Am J Med 1993;94:350-356. (Pubitemid 23106620)
11. Mandard S, Muller M, Kersten S. Peroxisome proliferatoractivated receptor α target genes. Cell Mol Life Sci 2004;61: 393-416. (Pubitemid 38316578)
12. Patsouris D, Mandard S, Voshol PJ., et al. PPARα governs glycerol metabolism. J Clin Invest 2004;114:94-103.
13. Barbier O, Villeneuve L, Bocher V, et al. The UDP glucuronosyltransferase 1A9 enzyme is a peroxisome proliferatoractivated receptor α and γ target gene. J Biol Chem 2003; 278:13975-13983. (Pubitemid 36799940)
14. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-580. (Pubitemid 43326861)
15. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:4312-4317. (Pubitemid 27194238)
16. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR)γ: adiposepredominant expression and induction early in adipocyte differentiation. Endocrinol 1994;135:798-800. (Pubitemid 24241266)
17. Marx N, Sch?nbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-1103. (Pubitemid 28533518)
18. Bell DSH. β-cell rejuvenation with thiazolidinediones. Am J Med 2003;115:20-23.
19. Yki-Jarvinen H. Thiazolidinediones. The New Engl J Med 2004;351:1106-1118.
20. Al-Khalili L, Forsgren M, Kannisto K, Zierath JR, L?nnqvist F, Krook A. Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor γ co-activator 1. Diabetologia 2005;48:1173-1179. (Pubitemid 40909654)
21. Lehrke M, Lazar MA. The many faces of PPARγ. Cell 2005;123:993-999.
22. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertension 2004;22:2253-2261. (Pubitemid 39625096)
23. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001;98: 5306-5311. (Pubitemid 32397124)
24. Barish GD, Narkar VA, Evans RM. PPAR δ: a dagger in the heart of the metabolic Syndrome. J Clin Invest 2006;116: 590-597. (Pubitemid 43326863)
25. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Sci 2003;302: 453-457. (Pubitemid 37296272)
26. Shi Y, Hon M, Evans RM. The peroxisome proliferatoractivated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2002;99:2613-2618. (Pubitemid 34240509)
27. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2000;97:13275-13280.
28. Di-Pö? N, Michalik L, Tan NS, Desvergne B, Wahli W. The anti-apoptotic role of PPARβ contributes to efficient skin wound healing. J Steroid Bioc Mol Biol 2003;85: 257-265. (Pubitemid 37011101)
29. Liou JY, Lee S, Ghelani D, Matijevie-Aleksie N, Wu KK. Protection of endothelial survival by peroxisome proliferator activated receptor- δ mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006;26:1481-1487. (Pubitemid 44288972)
30. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α: direct role in obesitylinked insulin resistance. Sci 1993a;259:87-91. (Pubitemid 23036092)
31. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Bioc Soc Trans 2005;33:1078-1081. (Pubitemid 41659117)
32. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero, P., Larreal-Urdaneta, C., Lee, D. and Goldberg, R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006;71:92-100. (Pubitemid 41821148)
33. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97: 3A-11A. (Pubitemid 43139714)
34. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. The Am J Clin Nutr 2006;83:461S-465S. (Pubitemid 44713219)
35. Hotamisligil GS. Inflammatory pathways and insulin action. Intl J Obesity Related Metabolic Disorders 2003;27: S53-S55. (Pubitemid 38019190)
36. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE,White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-1537. (Pubitemid 34968910)
37. Nguyen MTA, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280: 35361-35371. (Pubitemid 41532725)
38. Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor ?B kinase complex. J Biol Chem 2002;277:48115-48121. (Pubitemid 35470759)
39. Bonora E. Themetabolic syndrome and cardiovascular disease. Ann Med 2006;38:64-80.
40. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-?B and AP-1. J Biol Chem 1999b;274:32048-32054.
41. Gervois P, Vu-Dac N, Kleemann R, et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem 2001;276:33471-33477.
42. Gervois P, Kleemann R, Pilon A, et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator activated receptor-α activator fenofibrate. J Biol Chem 2004;279:16154-16160. (Pubitemid 38509307)
43. Stienstra R, Duval C, Muller M, Kersten S. PPARs, Obesity, and Inflammation PPAR. New York, NY: Hindawi Publishing Corporation, Volume 2007, Article ID 95974.
44. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830. (Pubitemid 38063705)
45. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 2001;276:41245-41254.
46. Takata Y, Kitami Y, Yang ZH, NakamuraM, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res 2002;91: 427-433. (Pubitemid 35034211)
47. Pasceri V, Wu HD, Willerson JT, and Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circ 2000; 101:235-238. (Pubitemid 30054148)
48. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003;113:159-170. (Pubitemid 36514968)
49. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nature Med 2004;10:1245-1250. (Pubitemid 39540443)
50. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, FishbeinMC, MeehanWP, HsuehWA. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circ 2000;101:1311-1318. (Pubitemid 30158620)
51. Law RE, Hsueh WA. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001;21:1891-1895. (Pubitemid 34219737)
52. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86. (Pubitemid 28079219)
53. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor γ(PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999; 66: 733-739. (Pubitemid 29532032)
54. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferatoractivated receptor-γ. Circ 2002;105:2296-2302. (Pubitemid 34535341)
55. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999;21:76-83. (Pubitemid 29036288)
56. Barroso I, Gurnell M, Crowley VEF, AgostiniM, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, ORahilly S. Dominant negative mutations in human PPAR-γ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
57. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension 2001; 38: 249-254. (Pubitemid 34224753)
58. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelindependent hypertension. Arterioscler Thromb Vasc Biol 2003;23: 45-51. (Pubitemid 36091624)
59. Tabernero A, Schoonjans C, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator activated receptor α protects against myocardial ischemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002;2:1-10.
60. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternak A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circ 1997;96:2137-2143.
61. Ericsson C, Hansten A, Nilsson J, Grip L, Svane B de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853. (Pubitemid 26099535)
62. Dandona P. Endothelium, Inflamation, and diabetes. Curr Diab Rep 2002;2(4):311-315.
63. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann, Neves MF, Schiffrin EL. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40:866-871. (Pubitemid 35434908)
64. Ikeda U, Shimpo M, Murakami Y, Shimada K. Peroxidsome proliferator-activated receptor-g ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension 2000;35:1232-1236. (Pubitemid 30413656)
65. Fruchart JC, Duriez P, Staels B. Peroxisome proliferasatoractivated receptor alpha activators regulates gene governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-257. (Pubitemid 29405915)
66. Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, Lamas S, Perez-Sala D. PPAR agonists amplify iNOS expression while inhibiting NFkB: Implications for mesangial cell activation by cytokines. Am Soc Nephrol 2002;13(9): 2223-2231. (Pubitemid 34925232)
67. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor-γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52-57. (Pubitemid 36091625)
68. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circ 2003;108:2805-2811. (Pubitemid 37498984)
69. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94: 1168-1178. (Pubitemid 38656403)
70. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, repress nuclear factor-kappa B signaling and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-32841. (Pubitemid 28557672)